Allarity TherapeuticsALLR +0.86%26 14-Day RSI is 35.44 as of Jul. 09, 2026. GuruFocus rates ALLR with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,419 Biotechnology companies, Allarity Therapeutics ranks better than 87.03% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Allarity Therapeutics 14-Day RSI Related Terms
ALLR vs NCEL, LPCN, PTN: 14-Day RSI Comparison
For the Biotechnology subindustry, Allarity Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allarity Therapeutics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Allarity Therapeutics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allarity Therapeutics (ALLR) has a 14-Day RSI of 35.44 as of Jul. 09, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Allarity Therapeutics and its competitors. According to the industry distribution chart, Allarity Therapeutics ranks #184 out of 1419 companies in the Biotechnology industry, placing it in the top 13%.
Is Allarity Therapeutics' 14-Day RSI too high?
Allarity Therapeutics' current 14-Day RSI is 35.44. The Biotechnology industry median 14-Day RSI is 48.75. Allarity Therapeutics' value of 35.44 is 27.3% below this industry median. Based on the distribution chart, Allarity Therapeutics ranks #184 out of 1419 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Allarity Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' 14-Day RSI compare to NCEL and LPCN?
According to the Biotechnology industry distribution chart, Allarity Therapeutics ranks #184 out of 1419 companies for 14-Day RSI. This places Allarity Therapeutics in the top 13% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 48.75. Allarity Therapeutics' value of 35.44 is 27.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.75, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allarity Therapeutics's current 14-Day RSI of 35.44 is 27.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Allarity Therapeutics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allarity Therapeutics's current 14-Day RSI is 35.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (ALLR) has a current 14-Day RSI of 35.44. The current 14-Day RSI is 35.44 and 27.3% below the Biotechnology industry median of 48.75. Allarity Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Allarity Therapeutics (ALLR), the current 14-Day RSI is 35.44 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
26GF Score
Get the complete analysis for ALLR
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALLR has been successfully added to your 